Skip to content
Subscriber Only

Moderna Analysts Plan Reckoning After Valuation Declines

Updated on

Moderna Inc.’s shares have lost more than a third of their value since a lofty IPO pricetag left some analysts bewildered. This week, Wall Street will look at prospects for the company’s potential new class of medicines to assess its new valuation.

An analyst quiet period that expires on Wednesday applies to perhaps the most friendly analysts on the Street: those working at the banks that underwrote Moderna’s initial public offering. Initiations are likely to be published by firms including Morgan Stanley, Goldman Sachs, JPMorgan, Barclays, Bank of America Merrill Lynch, Piper Jaffray, Oppenheimer and Needham.